Investor News

System-c bioprocess, Aurogene and Labsoft have recently been appointed to respectively represent Phase Holographic Imaging (PHI) in France, Italy and Poland.

For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.

A major publicly traded life science tools company has entered a technology assessment agreement with Phase Holographic Imaging (PHI). The purpose of the agreement is to assess PHI’s Holo¬Monitor technology for cell biology applications, primarily within immuno-oncology.

In June 2018, Phase Holographic Imaging (PHI) and BioSpherix Medical entered a collaboration agreement, aiming to co-market the companies’ complementary product lines. BioSpherix develops and market advanced hermetically sealed cell incubators for the control and optimization of cell culture environments.

Scientists at the Holographic Imaging Cytometry Center of Excellence at University of California, San Francisco, study how normal skin cells transform into aggressive skin cancer. HoloMonitor M4 plays an important role in their research.

Melanoma, the most dangerous form of skin cancer, is increasing. In the US, melanoma is one of the most common cancers among young adults. However, if the disease is caught early, then it can be cured. A research team, led by Dr Robert Judson-Torres, is tracking single cells when studying melanoma at an early stage.

Tests on animals are routinely used in many research areas, including pre-clinical drug development and testing of chemicals and cosmetics. Today, there is a growing interest in developing alternatives to research methods that involves living animals, and also to replace animal derived components used in different kind of products.

Understanding of cell movements is essential in many aspects of cell biology research, and crucial not least in cancer research.

For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.

Baserat på PHI:s befintliga HoloMonitor-teknik, har institutionen för Immun­teknologi vid Lunds Universitet och Phase Holographic Imaging (PHI) avtalat om att gemensamt utveckla nya metoder för 3‑dimensionell cell­odling. Detta för att möta ett akut och snabbt växande behov av dessa metoder inom cancerforskningen.